| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | palmostatin B | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.0022 | 0.9 |